Completed PHASE2 INTERVENTIONAL 1-arm NCT04002284

Anlotinib in Metastatic HER2 Negative Breast Cancer

The Efficacy and Safety of Anlotinib in Metastatic HER2 Negative Breast Cancer, a Single Arm Phase II Clinical Trial

Sponsor: Peng Yuan

Conditions Anlotinib Antineoplastic Agents Breast Neoplasm

Updated 7 times since 2019 Last updated: Jul 27, 2020 Started: Jul 12, 2018 Primary completion: Jan 10, 2020 Completion: Mar 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04002284, this PHASE2 trial focuses on Anlotinib and Antineoplastic Agents and remains completed. Sponsored by Peng Yuan, it has been updated 7 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Oct 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Aug 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jul 2019 — Aug 2020 [monthly]

Recruiting PHASE2

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peng Yuan

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China